Industry
Biotechnology
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Loading...
Open
17.29
Mkt cap
1.6B
Volume
873K
High
17.66
P/E Ratio
-6.30
52-wk high
32.52
Low
16.65
Div yield
N/A
52-wk low
15.97
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 10:14 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 8:15 pm
Portfolio Pulse from Benzinga Newsdesk
July 03, 2024 | 2:21 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 7:05 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 2:51 pm
Portfolio Pulse from Vandana Singh
June 28, 2024 | 1:52 pm
Portfolio Pulse from Avi Kapoor
June 28, 2024 | 1:08 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 12:18 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 11:55 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.